American Journal of Cardiology
Volume 104, Issue 2 , Pages 247-253 , 15 July 2009

Prognostic Value of Multiple Biomarkers in American Indians Free of Clinically Overt Cardiovascular Disease (from the Strong Heart Study)

  • Jorge R. Kizer, MD, MSc

      Affiliations

    • Department of Medicine, Weill Cornell Medical Center, New York, New York
    • Department of Public Health, Weill Cornell Medical Center, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: 212-746-2642; fax: 212-746-8561
    • ,
  • Daniel G. Krauser, MD

      Affiliations

    • Department of Medicine, Weill Cornell Medical Center, New York, New York
    • ,
  • Richard J. Rodeheffer, MD

      Affiliations

    • Division of Cardiovascular Diseases, Mayo Clinic Foundation, Rochester, Minnesota
    • ,
  • John C. Burnett Jr., MD

      Affiliations

    • Department of Physiology, Mayo Clinic Foundation, Rochester, Minnesota
    • Department of Internal Medicine, Mayo Clinic Foundation, Rochester, Minnesota
    • ,
  • Peter M. Okin, MD

      Affiliations

    • Department of Medicine, Weill Cornell Medical Center, New York, New York
    • ,
  • Mary J. Roman, MD

      Affiliations

    • Department of Medicine, Weill Cornell Medical Center, New York, New York
    • ,
  • Jason G. Umans, MD, PhD

      Affiliations

    • MedStar Research Institute, Washington, District of Columbia
    • ,
  • Lyle G. Best, MD

      Affiliations

    • Missouri Breaks Industries Research, Inc., Timber Lake, South Dakota
    • ,
  • Elisa T. Lee, PhD

      Affiliations

    • College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
    • ,
  • Richard B. Devereux, MD

      Affiliations

    • Department of Medicine, Weill Cornell Medical Center, New York, New York

Received 4 February 2009 ,Revised 12 March 2009 ,Accepted 12 March 2009.

References 

  1. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  2. Howard BV, Best LG, Galloway JM, Howard WJ, Jones K, Lee ET, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29:391–397
  3. Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS. Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care. 2003;26:2777–2784
  4. Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci Lond. 2001;101:671–679
  5. Yang X, So WY, Kong AP, Ma RC, Ko GT, Ho CS, et al. Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol. 2008;101:596–601
  6. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–843
  7. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–1809
  8. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241–2247
  9. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med. 2004;141:413–420
  10. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368
  11. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655–663
  12. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421–426
  13. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293:1609–1616
  14. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, et al. Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 2006;114:201–208
  15. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med. 2006;145:21–29
  16. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, Larsson A, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med. 2008;358:2107–2116
  17. Lee ET, Welty TK, Fabsitz R, Cowan LD, Le NA, Oopik AJ, et al. The Strong Heart Study (A study of cardiovascular disease in American Indians: design and methods). Am J Epidemiol. 1990;132:1141–1155
  18. Best LG, Zhang Y, Lee ET, Yeh JL, Cowan L, Palmieri V, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation. 2005;112:1289–1295
  19. Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA, et al. Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic American Indian women: the Strong Heart Study. J Womens Health. 2004;13:155–163
  20. Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, et al. Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J. 2003;145:467–474
  21. Lu WQ, Resnick HE, Jablonski KA, Jain AK, Jones KL, Robbins DC, et al. Effects of glycaemic control on cardiovascular disease in diabetic American Indians: the Strong Heart Study. Diabet Med. 2004;21:311–317
  22. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172
  23. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–2639
  24. Standards of medical care in diabetes—2009. Diabetes Care. 2009;32(suppl):S13–S61
  25. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  26. Davidson M, Zhu J, Lu W, Tracy RP, Robbins DC, Resnick HE, et al. Plasminogen activator inhibitor-1 and the risk of type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006;23:1158–1159

 This study was supported by Grants U01-HL41642, U01-HL41652, U01-HL41654, and U01-HL65521 and by Awards K23-HL070854 (to Dr. Kizer) and R01-HL55502 (to DR. Rodeheffer) from the National Heart, Lung, and Blood Institute, Bethesda, Maryland, and by Grant M10RR0047 (General Clinical Research Center) from the National Institutes of Health, Bethesda, Maryland.

PII: S0002-9149(09)00736-X

doi: 10.1016/j.amjcard.2009.03.026

American Journal of Cardiology
Volume 104, Issue 2 , Pages 247-253 , 15 July 2009

Article Tools